Aytu BioPharma is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics and consumer health products. The Company’s prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), as well as Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Aytu’s consumer health segment markets a range of over-the-counter medicines, personal care products, and dietary supplements addressing a range of common conditions including diabetes, allergy, hair regrowth, and gastrointestinal conditions. To learn more, please visit aytubio.com.
Company profile
Ticker
AYTU
Exchange
Website
CEO
Joshua R. Disbrow
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AYTU BIOSCIENCE, INC, Rosewind CORP
SEC CIK
Corporate docs
Subsidiaries
Aytu Therapeutics, LLC • Innovus Pharmaceuticals, Inc. • Semprae Laboratories, Inc • Supplement Hunt, Inc. • Delta Prime Savings Club, Inc • Neos Therapeutics, Inc. • Neos Therapeutics Brands, LLC • Neos Therapeutics, LP • PharmaFab Texas, LLC ...
AYTU stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
27 Mar 23
10-Q
2023 Q2
Quarterly report
21 Feb 23
8-K
Aytu BioPharma Reports Second Quarter of Fiscal Year 2023
21 Feb 23
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
21 Feb 23
NT 10-Q
Notice of late quarterly filing
15 Feb 23
8-K
Aytu BioPharma Announces Delayed Filing of Second Quarter Fiscal 2023 Financial Results
14 Feb 23
8-K
Departure of Directors or Certain Officers
13 Feb 23
8-K
Regulation FD Disclosure
25 Jan 23
8-K
Aytu BioPharma Announces 1-for-20 Reverse Stock Split
5 Jan 23
Transcripts
AYTU
Earnings call transcript
2023 Q2
21 Feb 23
AYTU
Earnings call transcript
2023 Q1
14 Nov 22
AYTU
Earnings call transcript
2022 Q4
28 Sep 22
AYTU
Earnings call transcript
2022 Q1
16 Nov 21
AYTU
Earnings call transcript
2021 Q4
27 Sep 21
AYTU
Earnings call transcript
2021 Q3
18 May 21
AYTU
Earnings call transcript
2021 Q2
12 Feb 21
AYTU
Earnings call transcript
2020 Q3
14 May 20
AYTU
Earnings call transcript
2020 Q2
13 Feb 20
AYTU
Earnings call transcript
2020 Q1
14 Nov 19
Latest ownership filings
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Jun 22 | Jun 21 | Jun 20 | Jun 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 19.50 mm | 19.50 mm | 19.50 mm | 19.50 mm | 19.50 mm | 19.50 mm |
| Cash burn (monthly) | 1.44 mm | 1.31 mm | 2.26 mm | 6.75 mm | 813.33 k | 2.32 mm |
| Cash used (since last report) | 4.28 mm | 3.92 mm | 6.75 mm | 20.13 mm | 2.42 mm | 6.91 mm |
| Cash remaining | 15.22 mm | 15.58 mm | 12.75 mm | -626.51 k | 17.08 mm | 12.59 mm |
| Runway (months of cash) | 10.6 | 11.9 | 5.6 | -0.1 | 21.0 | 5.4 |
Institutional ownership, Q3 2022
18.8% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 55 |
| Opened positions | 13 |
| Closed positions | 2 |
| Increased positions | 10 |
| Reduced positions | 10 |
| 13F shares | Current |
|---|---|
| Total value | 2.91 mm |
| Total shares | 12.19 mm |
| Total puts | 0.00 |
| Total calls | 117.70 k |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| CVI Investments | 3.40 mm | $959.00 k |
| Renaissance Technologies | 1.75 mm | $323.00 k |
| Alyeska Investment | 1.50 mm | $278.00 k |
| Sabby Management | 1.26 mm | $234.00 k |
| Vanguard | 972.70 k | $180.00 k |
| Walleye Capital | 582.50 k | $108.00 k |
| BLK Blackrock | 481.75 k | $89.00 k |
| Ayrton Capital | 452.22 k | $84.00 k |
| Millennium Management | 409.84 k | $76.00 k |
| Geode Capital Management | 241.55 k | $44.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 8 Feb 23 | Vivian H Liu | Common Shares | Grant | Acquire A | No | No | 0 | 6,500 | 0.00 | 6,825 |
| 21 Dec 22 | Carl Dockery | Common Stock | Sale back to company | Dispose D | No | No | 0 | 40,000 | 0.00 | 148,805 |
| 21 Dec 22 | Cantrell Gary | Common Stock | Sale back to company | Dispose D | No | No | 0 | 40,000 | 0.00 | 164,089 |
| 21 Dec 22 | Donofrio John Jr. | Common Stock | Sale back to company | Dispose D | No | No | 0 | 187,804 | 0.00 | 15,267 |
| 20 Dec 22 | Disbrow Joshua R. | Common Stock | Sale back to company | Dispose D | No | No | 0 | 80,000 | 0.00 | 1,151,877 |
News
Press releases
Aytu BioPharma Reports Second Quarter of Fiscal Year 2023
21 Feb 23
Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 21, 2023
21 Feb 23
Aytu BioPharma Announces Delayed Filing of Second Quarter Fiscal 2023 Financial Results
14 Feb 23
Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 14, 2023
7 Feb 23
Aytu BioPharma Regains Nasdaq Minimum Bid Price Compliance
25 Jan 23